Last reviewed · How we verify
Selective serotonin reuptake inhibitor
At a glance
| Generic name | Selective serotonin reuptake inhibitor |
|---|---|
| Also known as | SSRI, CBT |
| Sponsor | University of Washington |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study of Electrophysiological Markers of Antidepressants in Major Depressive Disorder (NA)
- Intradermal Acupuncture for Assisting SSRI Dose Reduction in Major Depressive Disorder (NA)
- Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease (PHASE2)
- Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms (PHASE3)
- A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI)
- Effect of Virtual Reality on Depression in Adolescent Females (NA)
- MAGNESIUM & SSRI VS SSRI ALONE AMONG PATIENTS OF MAJOR DEPRESSIVE DISORDER (PHASE2)
- Pattern Separation in Major Depressive Disorder (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: